Moberg Pharma AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.mobergderma.se
A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis
Not Applicable
Completed
- Conditions
- Onychomycosis
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 75
- Registration Number
- NCT01180491
K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2010-06-04
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 201
- Registration Number
- NCT01137331
- Locations
- 🇸🇪
Fruängens Läkarhus, Hägersten, Sweden
🇸🇪Hudläkarna i Linköping, Linköping, Sweden
🇸🇪Möllevångens Husläkargrupp, Malmo, Sweden
Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp
Phase 2
Completed
- Conditions
- Seborrhoeic Dermatitis of the Scalp
- Interventions
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2010-06-04
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 98
- Registration Number
- NCT01137630
- Locations
- 🇸🇪
Hedesunda Hälsocentral, Hedesunda, Sweden
🇸🇪Stortorgets Hälsocentral, Gävle, Sweden
🇸🇪Derbykliniken, Malmo, Sweden
Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2009-11-06
- Lead Sponsor
- Moberg Pharma AB
- Registration Number
- NCT00863005
- Locations
- 🇩🇪
bioskin GmbH, Hamburg, Germany
© Copyright 2025. All Rights Reserved by MedPath